• RMIT Australia
  • RMIT Global
  • RMIT Australia
  • RMIT Europe
  • RMIT Vietnam

• Students
• Alumni
• Staff

Research Repository

Back to Library

• Home
• Browse
• Search
• FAQs
• About
• Contact Us

Anti-atherogenic role of Peroxisome Proliferator Activated Receptor ligands Nigro, J, Ballinger, M, Osman, N, Dart, A and Little, P 2005, 'Anti-atherogenic role of Peroxisome Proliferator Activated Receptor ligands', Current Cardiology Reviews, vol. 1, pp. 89-102. Document type: Journal Article Collection: Journal Articles Title Anti-atherogenic role of Peroxisome Proliferator Activated Receptor ligands Author(s) Nigro, J Ballinger, M Osman, N Dart, A Little, P Year 2005 Journal name Current Cardiology Reviews Volume number 1 Start page 89 End page 102 Total pages 14 Publisher Bentham Science Publishers Abstract Two families of peroxisome proliferating-activated receptor (PPAR) ligands are utilized clinically to address abnormalities of blood-borne cardiovascular risk factors. PPAR-a ligands, the fibrates, lower plasma triglycerides and increase high-density lipoprotein (HDL)-cholesterol leading to positive outcomes in clinical trials such as the Veterans Affairs HDL Intervention Trial. PPAR-? ligands, the recently introduced family of thiazolidinediones, act as insulin sensitizers to alleviate the hyperglycemia of insulin resistant states such as Type 2 diabetes. The primary aim of treating the cardiovascular risk factors is to reduce the burden of cardiovascular disease, mostly atherosclerotic vascular disease. Considerable evidence is emerging that PPAR ligands can exert anti-atherogenic activity. Although the agents acting on their target nuclear receptors are primarily regulators of gene transcription it may be that some actions are independent of gene transcription and represent direct inhibition of atherogenic signalling pathways in the vasculature. The direct actions including inhibition of vascular smooth muscle cell proliferation and inhibition of glycosaminoglycan elongation on proteoglycans, the latter leading to reduced low-density lipoprotein (LDL) binding, provide in vitro examples of antiatherogenic actions. Keyword(s) atherosclerosis cardiovascular disease fibrates glitazones lipoprotein retention peroxisome proliferating activated receptor (ppar) ISSN 1875-6557 Versions Version Filter Type Fri, 16 Jan 2015, 14:43:59 EST Filtered Full Access Statistics: 89 Abstract Views  -  Detailed Statistics Created: Thu, 15 Jan 2015, 13:42:00 EST by Catalyst Administrator